PE20080275A1 - Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa - Google Patents
Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasaInfo
- Publication number
- PE20080275A1 PE20080275A1 PE2007000877A PE2007000877A PE20080275A1 PE 20080275 A1 PE20080275 A1 PE 20080275A1 PE 2007000877 A PE2007000877 A PE 2007000877A PE 2007000877 A PE2007000877 A PE 2007000877A PE 20080275 A1 PE20080275 A1 PE 20080275A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclohepta
- benzo
- pyridine
- inhibitors
- tyrosine kinase
- Prior art date
Links
- PUBPOEZCQYLQHD-UHFFFAOYSA-N 5h-benzo[3,4]cyclohepta[1,4-b]pyridine Chemical class C1C=C2C=CC=CC2=CC2=NC=CC=C12 PUBPOEZCQYLQHD-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 4-METHYLBENZYL Chemical class 0.000 abstract 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 abstract 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 5H-BENZO[4,5]CICLOHEPTA[1,2]PIRIDINA DE FORMULA (I) DONDE R1 ES OH, O-ALQUILO(C1-C6), -S-ALQUILO(C1-C6), -S-ARILO, ENTRE OTROS; R2 Y R3 SON CADA UNO H, HALO, HETEROCICLILO(C=O)aOb, ObPERFLUOROALQUILO(C1-C6), ENTRE OTROS, DONDE a Y b SON CADA UNO 0 O 1; R4 Y R5 SON CADA UNO H, ALQUENILO(C2-C10), ALQUINILO(C2-C10), PERFLUOROALQUILO(C1-C3), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N,N-DIMETIL-1-[3-(1-METIL-1H-PIRAZOL-4-IL)-5-OXO-5H-BENZO[4,5]CICLOHEPTA[1,2-b]PIRIDIN-7-IL]METANOSULFONAMIDA, 1-[3-(1-METIL-1H-PIRAZOL-4-IL)-5-OXO-5H-BENZO[4,5]CICLOHEPTA[1,2-b]PIRIDIN-7-IL]-N-FENILMETANOSULFONAMIDA, N-(4-METILBENCIL)-1-[3-(1-METIL-1H-PIRAZOL-4-IL)-5-OXO-5H-BENZO[4,5]CICLOHEPTA[1,2-b]PIRIDIN-7-IL]METANOSULFONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR TIROSINA QUINASA MET SIENDO UTILES EN EL TRATAMIENTO DE CANCER, HIPERPLASIAS, REESTENOSIS, HIPERTROFIA CARDIACA, INFLAMACION, TRANSTORNOS INMUNITARIOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81976406P | 2006-07-10 | 2006-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080275A1 true PE20080275A1 (es) | 2008-04-03 |
Family
ID=38923821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000877A PE20080275A1 (es) | 2006-07-10 | 2007-07-05 | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8222269B2 (es) |
| EP (1) | EP2049494B1 (es) |
| JP (2) | JP4203121B1 (es) |
| KR (1) | KR20090026187A (es) |
| CN (1) | CN101535268B (es) |
| AR (1) | AR061804A1 (es) |
| AU (1) | AU2007273081B2 (es) |
| BR (1) | BRPI0713941A2 (es) |
| CA (1) | CA2656578C (es) |
| CO (1) | CO6190518A2 (es) |
| CR (1) | CR10560A (es) |
| EC (1) | ECSP099051A (es) |
| ES (1) | ES2497493T3 (es) |
| GT (1) | GT200900004A (es) |
| HN (1) | HN2009000018A (es) |
| IL (1) | IL196337A0 (es) |
| MA (1) | MA30631B1 (es) |
| MX (1) | MX2009000410A (es) |
| NO (1) | NO20090608L (es) |
| PE (1) | PE20080275A1 (es) |
| RU (1) | RU2009104303A (es) |
| TW (1) | TW200813021A (es) |
| WO (1) | WO2008008310A2 (es) |
| ZA (1) | ZA200900019B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE524445T1 (de) | 2005-06-23 | 2011-09-15 | Merck Sharp & Dohme | Benzocycloheptapyridine als inhibitoren der tyrosinkinase met |
| US7893081B2 (en) | 2007-12-20 | 2011-02-22 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CN102036560A (zh) * | 2008-05-21 | 2011-04-27 | 巴斯夫欧洲公司 | 取代吡啶-4-基甲基磺酰胺 |
| EP2482803B1 (en) * | 2009-09-30 | 2021-12-22 | Merck Sharp & Dohme (UK) Limited | Formulations for c-met kinase inhibitors |
| CA2771338A1 (en) * | 2009-09-30 | 2011-04-07 | Merck Sharp & Dohme Corp. | Crystalline hydrochloride salts of c-met kinase inhibitors |
| CA2798080C (en) | 2010-05-17 | 2020-08-25 | Incozen Therapeutics Pvt. Ltd. | 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| JP6192708B2 (ja) | 2012-03-30 | 2017-09-06 | ライゼン・ファーマシューティカルズ・エスアー | Ｃ−ｍｅｔプロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−イミダゾ［４，５−ｂ］ピリジン化合物および３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
| MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| WO2015017533A1 (en) * | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Ntrk2 fusions |
| WO2015017528A1 (en) * | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Pik3c2g fusions |
| WO2016091891A1 (en) | 2014-12-09 | 2016-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against axl |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| ES2966973T3 (es) * | 2016-06-17 | 2024-04-25 | Univ Pennsylvania | Compuestos, composiciones y métodos para la prevención y/o el tratamiento del cáncer |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL132137C (es) * | 1963-04-24 | |||
| US4826853A (en) | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
| JP2852659B2 (ja) * | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
| IL98572A (en) | 1990-06-22 | 1995-07-31 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compositions an methods of use |
| US6365588B1 (en) * | 1993-10-15 | 2002-04-02 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| ES2159047T3 (es) * | 1995-10-16 | 2001-09-16 | Kyowa Hakko Kogyo Kk | Compuestos triciclicos. |
| IL128949A0 (en) | 1996-09-13 | 2000-02-17 | Schering Corp | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| JP2001500506A (ja) | 1996-09-13 | 2001-01-16 | シェーリング コーポレイション | ファルネシルタンパク質トランスフェラーゼのインヒビターとして有用な置換ベンゾシクロヘプタピリジン |
| CA2460939C (en) * | 2001-09-19 | 2008-07-29 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
| AU2003230758A1 (en) | 2002-04-02 | 2003-10-20 | Merck And Co., Inc. | 5h-benzo(4,5)cyclohepta(1,2-b)pyridine nmda/nr2b antagonists |
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
| JP2006151809A (ja) | 2002-12-26 | 2006-06-15 | Ube Ind Ltd | ベンゾシクロヘプタピリジン化合物 |
| EP1768964A1 (en) * | 2004-07-06 | 2007-04-04 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
| TW200738638A (en) * | 2005-06-23 | 2007-10-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
| ATE524445T1 (de) * | 2005-06-23 | 2011-09-15 | Merck Sharp & Dohme | Benzocycloheptapyridine als inhibitoren der tyrosinkinase met |
-
2007
- 2007-07-02 TW TW096124020A patent/TW200813021A/zh unknown
- 2007-07-03 AR ARP070102972A patent/AR061804A1/es not_active Application Discontinuation
- 2007-07-05 PE PE2007000877A patent/PE20080275A1/es not_active Application Discontinuation
- 2007-07-06 EP EP07810282.9A patent/EP2049494B1/en active Active
- 2007-07-06 RU RU2009104303/04A patent/RU2009104303A/ru not_active Application Discontinuation
- 2007-07-06 WO PCT/US2007/015675 patent/WO2008008310A2/en active Application Filing
- 2007-07-06 CA CA2656578A patent/CA2656578C/en active Active
- 2007-07-06 JP JP2008536664A patent/JP4203121B1/ja active Active
- 2007-07-06 MX MX2009000410A patent/MX2009000410A/es not_active Application Discontinuation
- 2007-07-06 KR KR1020097000538A patent/KR20090026187A/ko not_active Ceased
- 2007-07-06 US US12/309,149 patent/US8222269B2/en active Active
- 2007-07-06 AU AU2007273081A patent/AU2007273081B2/en not_active Ceased
- 2007-07-06 ES ES07810282.9T patent/ES2497493T3/es active Active
- 2007-07-06 CN CN2007800335075A patent/CN101535268B/zh active Active
- 2007-07-06 BR BRPI0713941-1A patent/BRPI0713941A2/pt not_active Application Discontinuation
- 2007-07-09 US US11/827,109 patent/US8101603B2/en active Active
-
2008
- 2008-04-21 JP JP2008109902A patent/JP5245045B2/ja not_active Expired - Fee Related
-
2009
- 2009-01-01 IL IL196337A patent/IL196337A0/en unknown
- 2009-01-05 ZA ZA200900019A patent/ZA200900019B/xx unknown
- 2009-01-06 CO CO09000744A patent/CO6190518A2/es not_active Application Discontinuation
- 2009-01-07 HN HN2009000018A patent/HN2009000018A/es unknown
- 2009-01-09 GT GT200900004A patent/GT200900004A/es unknown
- 2009-01-09 EC EC2009009051A patent/ECSP099051A/es unknown
- 2009-01-14 CR CR10560A patent/CR10560A/es not_active Application Discontinuation
- 2009-02-09 MA MA31620A patent/MA30631B1/fr unknown
- 2009-02-09 NO NO20090608A patent/NO20090608L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
| PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
| PE20090546A1 (es) | Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5 | |
| PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| NO20080475L (no) | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20070490A1 (es) | Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1 | |
| NO20075082L (no) | Pyridin-3-karboksamidderivater som CB1-inversagonister | |
| PE20081887A1 (es) | Nuevo compuesto de adenina | |
| PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
| PE20081409A1 (es) | Antagonistas del receptor de progesterona | |
| PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
| DE602008001983D1 (de) | Pyrrolidinderivate als doppelte nk1/nk3-rezeptorenantagonisten | |
| IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
| PE20071311A1 (es) | Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu | |
| CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
| MX2010006230A (es) | Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3. | |
| PE20120218A1 (es) | Compuestos para el tratamiento de trastornos metabolicos | |
| PE20091077A1 (es) | Derivados de ciclopropilamida con actividad sobre los receptores h3 | |
| PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
| PL1620425T3 (pl) | Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu | |
| DE602006017837D1 (de) | Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |